Ayurcann Holdings EBIT

The latest EBIT for AYUR.CN is $-2.8M as of September 2025. That compares with $-4.5M in the prior-year period — up 36.8% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Ayurcann Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, AYUR.CN's EBIT moved from $-4.5M to $-2.8M — a 36.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ayurcann Holdings's operating scale or balance-sheet position.

Against its sector companies, AYUR.CN currently prints $-2.8M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Ayurcann Holdings's growth, margins, and balance sheet.

A EBIT figure of $-2.8M for AYUR.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting AYUR.CN's EBIT ($-2.8M), review year-over-year change from $-4.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.